Szigeti Andrea, Ecsedy Mónika, Schneider Miklós, Lénárt Lilla, Lesch Balázs, Nagy Zoltán Zsolt, Fekete Andrea, Récsán Zsuzsanna
Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
MTA-SE Lendület Diabetes Research Group, Research Laboratory for Pediatrics and Nephrology of the Hungarian Academy of Sciences and of the Semmelweis University, Budapest, Hungary.
PLoS One. 2016 Nov 10;11(11):e0166544. doi: 10.1371/journal.pone.0166544. eCollection 2016.
Stromal cell-derived factor 1 (SDF1) has crucial role in the regulation of angiogenesis and ocular neovascularisation (NV). The purpose of this study was to evaluate the association between SDF1-3'G(801)A polymorphism and NV complications of retinal vein occlusion (RVO).
130 patients with RVO (median age: 69.0, range 35-93 years; male/female- 58/72; 55 patients had central RVO, 75 patients had branch RVO) were enrolled in this study. In the RVO group, 40 (30.8%) patients were diagnosed with NV complications of RVO and 90 (69.2%) patients without NVs. The median follow up period was 40.3 months (range: 18-57 months). The SDF1-3'G(801)A polymorphism was detected by PCR-RFLP. Allelic prevalence was related to reference values obtained in the control group consisted of 125 randomly selected, age and gender matched, unrelated volunteers (median age: 68.0, range 36-95 years; male/female- 53/72). Statistical analysis of the allele and genotype differences between groups (RVO patients vs controls; RVO patients with NV vs RVO patients without NV) was determined by chi-squared test. P value of <0.05 was considered statistically significant.
Hardy-Weinberg criteria was fulfilled in all groups. The SDF1-3'G(801)A allele and genotype frequencies of RVO patients were similar to controls (SDF1-3'A allele: 22.3% vs 20.8%; SDF1-3'(801)AA: 5.4% vs 4.8%, SDF1-3'(801)GG: 60.8% vs 63.2%). The frequency of SDF1-3'(801)AA and SDF1-3'(801)GA genotypes, as well as the SDF1-3'(801)A allele frequency were higher in RVO patients with NV versus in patients without NV complication (SDF1-3'(801)AA+AG genotypes: 57.5% vs 31.1%, p = 0.008; SDF1-3'(801)A allele: 35.0% vs 16.7%, p = 0.002) or versus controls (SDF1-3'(801)AA+AG genotypes 57.5% vs 36.8%, p = 0.021; SDF1-3'(801)A allele: 35.0% vs 20.8% p = 0.01). Carrying of SDF1-3'(801)A allele increased the risk of neovascularisation complications of RVO by 2.69 (OR, 95% CI = 1.47-4.93).
These findings suggest that carrying SDF1-3'(801)A allele plays a role in the development of neovascular complications in retinal vein occlusion.
基质细胞衍生因子1（SDF1）在血管生成和眼部新生血管形成（NV）的调控中起关键作用。本研究旨在评估SDF1 - 3'G(801)A多态性与视网膜静脉阻塞（RVO）的NV并发症之间的关联。
130例RVO患者（中位年龄：69.0岁，范围35 - 93岁；男/女 = 58/72；55例为中央RVO，75例为分支RVO）纳入本研究。在RVO组中，40例（30.8%）患者被诊断为RVO的NV并发症，90例（69.2%）患者无NV。中位随访期为40.3个月（范围：18 - 57个月）。通过聚合酶链反应 - 限制性片段长度多态性（PCR - RFLP）检测SDF1 - 3'G(801)A多态性。等位基因频率与由125名随机选择的、年龄和性别匹配的无关志愿者组成的对照组中的参考值相关（中位年龄：68.0岁，范围36 - 95岁；男/女 = 53/72）。通过卡方检验确定组间（RVO患者与对照组；有NV的RVO患者与无NV的RVO患者）等位基因和基因型差异的统计分析。P值<0.05被认为具有统计学意义。
所有组均符合哈迪 - 温伯格标准。RVO患者的SDF1 - 3'G(801)A等位基因和基因型频率与对照组相似（SDF1 - 3'A等位基因：22.3%对20.8%；SDF1 - 3'(801)AA：5.4%对4.8%，SDF1 - 3'(801)GG：60.8%对63.2%）。与无NV并发症的患者相比，有NV的RVO患者中SDF1 - 3'(801)AA和SDF1 - 3'(801)GA基因型的频率以及SDF1 - 3'(801)A等位基因频率更高（SDF1 - 3'(801)AA + AG基因型：57.5%对31.1%，p = 0.008；SDF1 - 3'(801)A等位基因：35.0%对16.7%，p = 0.002），或与对照组相比（SDF1 - 3'(801)AA + AG基因型57.5%对36.8%，p = 0.021；SDF1 - 3'(801)A等位基因：35.0%对20.8%，p = 0.01）。携带SDF1 - 3'(
